Hyderabad-based Dr. Reddy's Laboratories and MediCane Health Inc. have announced the launch of their therapeutic cannabis product in Germany.

Under a collaboration between Dr. Reddy's and MediCane that began in 2021, MediCane will supply medical cannabis products to Dr. Reddy's from its EU GMP-certified facilities based in Portugal, while providing logistical and regulatory support. 

As the exclusive distributor of the products in Germany, Dr. Reddy's will provide access to medicinal cannabis products, from MediCane, under its own brand, with the support of a field team, specialized and able to provide healthcare professionals training on the use of the products as well as advice on the process of reimbursement by health insurance.

This launch marks MediCane's entry into the pharmaceutical sector of a major European market. For Dr. Reddy's, this launch strengthens its presence in the growing German medical cannabis market, a presence already strengthened since the company's recent acquisition of Nimbus Health GmbH, specializing in the distribution, registration, sale and the commercialization of therapeutic cannabis.

Dr. Reddy's and MediCane have also signed an agreement to co-fund a Phase II clinical trial of a cannabis-based product for the relief of behavioral and psychological symptoms of dementia (BPSD). Upon completion of this trial, Dr. Reddy's will have exclusive rights to sell and market said product in Europe (excluding Russia and CIS countries). The parties plan to start the clinical trial of the product in the second half of 2022. BPSD refers to the spectrum of non-cognitive and non-neurological symptoms commonly seen in dementia, such as agitation, aggression, psychosis, depression and apathy.